To evaluate the role of functional p53 on the effect of Plk1 inhibition, NSCLC cells with different p53 status were treated with volasertib (0–85 nm) for 24 or 72 h, whereafter survival was assessed using the SRB assay. Here, PLK1 is linked to non-small cell lung carcinoma.